

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM647822

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
DERMAVANT SCIENCES GMBH		05/14/2021	Limited Liability Company: SWITZERLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	U.S. BANK NATIONAL ASSOCIATION		
<b>Street Address:</b>	One Federal Street, 3rd Floor		
<b>Internal Address:</b>	EX-MA-FED		
<b>City:</b>	Boston		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02110		
<b>Entity Type:</b>	National Banking Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5440964	DERMAVANT	
<b>Registration Number:</b>	5441037	DERMAVANT	
<b>Registration Number:</b>	5796949	DERMAVANT	
<b>Registration Number:</b>	5935231	DERMAVANT	
<b>Registration Number:</b>	5935386		
<b>Serial Number:</b>	90473679	QNUVU	
<b>Serial Number:</b>	90401644	TAQTEF	
<b>Serial Number:</b>	90401654	VTAMA	
<b>Serial Number:</b>	90702950		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	858-509-4071		
<b>Email:</b>	sdipdocket@pillsburylaw.com		
<b>Correspondent Name:</b>	Michelle L. Mehok		
<b>Address Line 1:</b>	12255 El Camino Real, Suite 300		
<b>Address Line 4:</b>	San Diego, CALIFORNIA 92130		

CH \$240.00 5440964

<b>ATTORNEY DOCKET NUMBER:</b>	258340-000091
<b>NAME OF SUBMITTER:</b>	Michelle L. Mehok
<b>SIGNATURE:</b>	/michelle mehok/
<b>DATE SIGNED:</b>	05/18/2021

**Total Attachments: 17**

source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page1.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page2.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page3.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page4.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page5.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page6.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page7.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page8.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page9.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page10.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page11.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page12.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page13.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page14.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page15.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page16.tif  
source=Dermavant - Trademark Security Agreement (RIPSA) [executed] 4850-2340-9129 v.1#page17.tif

**THE COLLATERAL AGENT IS PARTY TO THE SENIOR LENDER INTERCREDITOR AGREEMENT DATED AS OF MAY 14, 2021 WITH XYQ LUXCO S.À R.L., AS SENIOR LENDER, AND THE OTHER PARTIES PARTY THERETO FROM TIME TO TIME, BY WHICH THE COLLATERAL AGENT AND ITS SUCCESSORS AND ASSIGNS, ARE BOUND. THE TERMS OF THIS TRADEMARK SECURITY AGREEMENT, INCLUDING WITHOUT LIMITATION ANY RIGHTS OF ENFORCEMENT HEREUNDER, ARE SUBJECT TO THE TERMS OF SUCH SENIOR LENDER INTERCREDITOR AGREEMENT. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS HEREUNDER AND THE TERMS OF SUCH SENIOR LENDER INTERCREDITOR AGREEMENT, THE TERMS OF SUCH SENIOR LENDER INTERCREDITOR AGREEMENT WILL GOVERN AND CONTROL.**

**THE COLLATERAL AGENT IS PARTY TO THE PARITY INTERCREDITOR AGREEMENT DATED AS OF MAY 14, 2021, BY WHICH THE COLLATERAL AGENT AND ITS SUCCESSORS AND ASSIGNS, ARE BOUND. THE TERMS OF THIS TRADEMARK SECURITY AGREEMENT, INCLUDING WITHOUT LIMITATION ANY RIGHTS OF ENFORCEMENT HEREUNDER, ARE SUBJECT TO THE TERMS OF SUCH PARITY INTERCREDITOR AGREEMENT. IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS HEREUNDER AND THE TERMS OF SUCH PARITY INTERCREDITOR AGREEMENT, THE TERMS OF SUCH PARITY INTERCREDITOR AGREEMENT WILL GOVERN AND CONTROL.**

### **TRADEMARK SECURITY AGREEMENT**

This **TRADEMARK SECURITY AGREEMENT** is dated as of May 14, 2021 (this "Agreement"), by and between **DERMAVANT SCIENCES GMBH**, a limited liability company (Gesellschaft mit beschränkter Haftung) organized under the laws of Switzerland (the "Grantor"), and **U.S. BANK NATIONAL ASSOCIATION**, in its capacity as collateral agent under the RIPSAs referred to below with the address listed on its signature page hereto (in such capacity, including its successors and assigns, the "Collateral Agent").

### **PRELIMINARY STATEMENT**

WHEREAS the Grantor has entered into that certain Revenue Interest Purchase and Sale Agreement dated as of the date hereof (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the "RIPSA") with the Collateral Agent;

WHEREAS, as a condition to XYQ Luxco S.à r.l., NovaQuest Co-Investment Fund XVII, L.P. and MAM Tapir Lender, LLC (collectively, the "Purchasers") and the Collateral Agent entering into the RIPSAs, the Grantor has entered into that certain RIPSAs Collateral Agreement dated as of the date hereof (as may be amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the "RIPSA Collateral Agreement");

WHEREAS, pursuant to the terms of the RIPSAs Collateral Agreement, the Grantor has agreed to grant to the Collateral Agent, for the benefit of the Secured Parties (as defined in the RIPSAs Collateral Agreement), a continuing security interest in and lien on, the Collateral (as defined in the RIPSAs Collateral Agreement), including the Grantor's right, title and interest in and to all

present and future trademarks and related licenses and rights for the benefit of the Secured Parties; and

WHEREAS, pursuant to the RIPSAs Collateral Agreement, the Grantor is required to execute and deliver to the Collateral Agent this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby agrees as follows:

I. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the respective meanings given to them in the RIPSAs Collateral Agreement or, if not defined therein, in the RIPSAs.

II. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL. The Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, on the terms set forth in and subject to the RIPSAs Collateral Agreement, a continuing lien and security interest (subject to the Intercreditor Agreements) in all of the Grantor's right, title and interest in, to and under the following, to the extent constituting Collateral, whether presently existing or hereafter created or acquired (collectively, the "Trademark Collateral"):

A. all of its trademark applications and registrations set forth in Schedule I hereto, excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application (the "Trademarks");

B. all goodwill of the business associated with the Trademarks; and

C. all products and proceeds of the Trademarks, including any claim by the Grantor against third parties for past, present or future (i) infringement or dilution of any Trademarks or any Trademarks licensed under any intellectual property license, including the right to receive any damages, (ii) injury to the goodwill associated with any Trademark or (iii) right to receive license fees, royalties and other compensation under any intellectual property license;

provided, however, that, for the avoidance of doubt, the Trademark Collateral shall not include, and the lien and security interest granted in this Agreement shall not attach to, the Excluded Assets of the type described in clause (2) of the definition thereof.

III. SECURITY FOR OBLIGATIONS. The grant of a lien and security interest in the Trademark Collateral by the Grantor pursuant to this Agreement secures prompt payment to the Secured Parties of the Obligations. This Agreement and the lien and security interest created hereby secures the payment and performance of the Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Agreement secures the payment of all amounts which constitute part of the Obligations (as defined in the RIPSAs Collateral Agreement) and would be owed by the Grantor to the Secured Parties, whether or not they are unenforceable or not allowable due to the existence of a proceeding commenced by or against

the Grantor under any provision of the Bankruptcy Code (or under any other applicable foreign bankruptcy, insolvency, receivership or similar law) or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

IV. RIPSA COLLATERAL AGREEMENT. The lien and security interest granted pursuant to this Agreement is granted in conjunction with the lien and security interests granted to the Collateral Agent pursuant to the RIPSA Collateral Agreement. The Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the lien and security interest in the Trademark Collateral made and granted hereby are more fully set forth in the RIPSA Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Agreement and the RIPSA Collateral Agreement, the RIPSA Collateral Agreement shall control.

V. AUTHORIZATION TO SUPPLEMENT. The Grantor hereby authorizes the Collateral Agent to modify this Agreement by amending Schedule I to include any new trademark rights constituting Trademark Collateral of the Grantor in accordance with the provisions of the RIPSA Collateral Agreement; provided, that, the Collateral Agent shall provide prior written notice to the Grantor of any such amendment or modification, including a copy of the proposed amendment or modification to Schedule I. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Schedule I or provide notice to the Grantor of same shall in any way affect, invalidate or detract from the Collateral Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

VI. LIMITATION BY LAW; SEVERABILITY OF PROVISIONS. All rights, remedies and powers provided in this Agreement may be exercised only to the extent that the exercise thereof does not violate any applicable provision of law, and all the provisions of this Agreement are intended to be subject to all applicable mandatory provisions of law that may be controlling and to be limited to the extent necessary so that they shall not render this Agreement invalid, unenforceable or not entitled to be recorded or registered, in whole or in part. The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.

VII. BINDING EFFECT. The provisions of this Agreement shall be binding upon and inure to the benefit of the respective representatives, successors, and permitted assigns of the parties hereto; provided, however, the Grantor shall not assign or delegate any of its rights or duties under this Agreement without the prior written consent of the Collateral Agent (other than pursuant to a transaction permitted under the RIPSA), and any attempted assignment without such consent shall be null and void. The rights and benefits of the Collateral Agent hereunder shall, if such Persons so agree, inure to any party acquiring any interest in the Obligations or any part thereof in accordance with the terms hereof or of the RIPSA Collateral Agreement.

VIII. CAPTIONS. The captions contained in this Agreement are for convenience of reference only, are without substantive meaning and should not be construed to modify, enlarge, or restrict any provision.

IX. TERMINATION AND RELEASE. This Agreement shall terminate in accordance with the RIPSAs Collateral Agreement.

X. ENTIRE AGREEMENT. This Agreement, together with the RIPSAs Collateral Agreement, other Loan Documents (as defined in the RIPSAs Collateral Agreement) and the other Security Documents, embodies the entire agreement and understanding between the Grantor and the Collateral Agent relating to the Trademark Collateral and supersedes all prior agreements and understandings between the Grantor and the Collateral Agent relating to the Trademark Collateral.

XI. COUNTERPARTS. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all such counterparts shall together constitute one and the same Agreement. Any counterpart may be executed by facsimile or other electronic (including PDF) transmission, and such facsimile or other electronic transmission shall be deemed an original.

XII. AMENDMENTS. Neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Collateral Agent and the Grantor with respect to which such waiver, amendment or modification is to apply, subject to any consent that may be required in accordance with the RIPSAs Collateral Agreement.

XIII. GOVERNING LAW. **THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW) EXCEPT TO THE EXTENT THAT LOCAL LAW GOVERNS THE CREATION, PERFECTION, PRIORITY OR ENFORCEMENT OF SECURITY INTERESTS.**

XIV. SWISS LIMITATIONS. Section 8.21 (Swiss Limitations) of the RIPSAs Collateral Agreement shall apply mutatis mutandis to this Agreement.

XV. CONCERNING THE COLLATERAL AGENT. It is expressly understood and agreed that U.S. Bank National Association is entering into this Agreement solely in its capacity as Collateral Agent as appointed pursuant to the RIPSAs and shall be entitled to all of the rights, privileges, immunities and protections under the RIPSAs as if such rights, privileges, immunities and protections were set forth herein.

[signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**DERMAVANT SCIENCES GMBH**

By: [Signature]  
Name: Marianne Romeo Dinsmore  
Title: Managing Director

**ACKNOWLEDGMENT**



State of \_\_\_\_\_  
Country of BERMUDA

Be it known that personally appeared before me  
Marianne Romeo Dinsmore who acknowledged  
herself to be the Managing Director  
of Dermavant Sciences GmbH.

In testimony whereof, I have unto set my hand this  
17<sup>th</sup> day of May, 2021.

[Signature]  
Notary Signature

Unlimited  
My Commission



ACCEPTED AND ACKNOWLEDGED BY:

U.S. BANK NATIONAL ASSOCIATION,  
as Collateral Agent  
One Federal Street, 3rd Floor  
EX-MA-FED  
Boston, MA 02110

By: [Signature]  
Name: Alison D.B. Nadeau  
Title: Vice President

ACKNOWLEDGMENT

State of Massachusetts  
Country of United States


Be it known that personally appeared before me  
Alison D.B. Nadeau who acknowledged himself/herself  
to be the Vice President  
of U.S. Bank National Association.

In testimony whereof, I have unto set my hand this  
13<sup>th</sup> day of May, 2021.

[Signature]  
Notary Signature

8/20/21

My Commission





**Schedule 1**  
to  
TRADEMARK SECURITY AGREEMENT

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
Argentina	Dermavant Sciences GmbH	DERMAVANT	5	3.759.168	Nov-16-2018	3.102.409	Aug-14-2020	Registered	Aug-14-2030
Argentina	Dermavant Sciences GmbH	DERMAVANT	42	3.759.169	Nov-16-2018	3.026.708	Sep-27-2019	Registered	Sep-27-2029
Argentina	Dermavant Sciences GmbH	DERMAVANT	44	3.759.170	Nov-16-2018	3.077.131	May-8-2020	Registered	May-8-2030
Argentina	Dermavant Sciences GmbH	QNUVU	5	3.976.258	Jan-18-2021			Pending	
Argentina	Dermavant Sciences GmbH	TAQTEF	5	3.976.259	Jan-18-2021			Pending	
Argentina	Dermavant Sciences GmbH	VTAWA	5	3.976.260	Jan-18-2021			Pending	
Australia	Dermavant Sciences GmbH	DERMAVANT	5, 42, 44	1969163	Nov-16-2018	1969163	Oct-8-2020	Registered	Nov-16-2028
Australia	Dermavant Sciences GmbH	Dermavant Drop Logo	5, 42, 44	1484337	Jun-11-2019	1484337	Jun-11-2019	Registered	Jun-11-2029
Australia	Dermavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Australia	Dermavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Dermavant Sciences GmbH								
Australia	Dermavant Sciences GmbH	VTAWA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	DERMAVANT	5	916288544	Nov-21-2018	916288544	Sep-24-2019	Registered	Sep-24-2029
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	DERMAVANT	42	916288838	Nov-21-2018	916288838	Sep-17-2019	Registered	Sep-17-2029
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	DERMAVANT	44	916289001	Nov-21-2018	916289001	Oct-1-2019	Registered	Oct-1-2029
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
	Dermavant Sciences GmbH								
Brazil	Dermavant Sciences GmbH	VTAWA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
	Dermavant Sciences GmbH								
Canada	Dermavant Sciences GmbH	DERMAVANT	5, 42, 44	1795531	Aug-11-2016	1059945	Oct-22-2019	Registered	Oct-22-2029
	Dermavant Sciences GmbH								
Canada	Dermavant Sciences GmbH	DERMAVANT	42	1931251	Nov-19-2018			Pending	
	Dermavant Sciences GmbH								
Canada	Dermavant Sciences GmbH	DERMAVANT Drop Logo	5, 42	1968173	Jun-10-2019			Pending	
	Dermavant Sciences								
Canada	Dermavant Sciences	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Der mavant Sciences GmbH								
Canada	Der mavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Canada	Der mavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
China	Der mavant Sciences GmbH	DERMAVANT	44	34982700	Nov-29-2018	34982700	Jul-28-2019	Registered	Jul-27-2029
China	Der mavant Sciences GmbH	DERMAVANT	42	34982701	Nov-29-2018	34982701	Jul-28-2019	Registered	Jul-27-2029
China	Der mavant Sciences GmbH	DERMAVANT	5	34982702	Nov-29-2018	34982702	Jul-28-2019	Registered	Jul-27-2029
China	Der mavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
China	Der mavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
China	Der mavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
EUTM	Der mavant Sciences GmbH	DERMAVANT	42	017986410	Nov-16-2018	017986410	May-11-2019	Registered	Nov-16-2028
EUTM	Der mavant Sciences GmbH	DERMAVANT	5, 44	15751217	Aug-11-2016	15751217	Aug-18-2020	Registered	Aug-11-2026
EUTM	Der mavant Sciences	Drop Logo	5, 42, 44	1484337	Jun-11-2019	1484337	Jun-11-2019	Registered	Jun-11-2029

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Dermavant Sciences GmbH								
EUTM	Dermavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
EUTM	Dermavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
EUTM	Dermavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
India	Dermavant Sciences GmbH	DERMAVANT	5, 42, 44	4011269	Nov-29-2018	4011269	Nov-29-2018	Registered	Nov-29-2028
India	Dermavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
India	Dermavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
India	Dermavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
International Register	Dermavant Sciences GmbH	Dermavant Drop Logo	5, 42, 44	1484337	Jun-11-2019	1484337	Jun-11-2019	Registered	Jun-11-2029
International Register	Dermavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Registered	Jan-18-2031
International Register	Dermavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Registered	Jan-18-2031
International Register	Dermavant Sciences	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Registered	Jan-18-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Derivant Sciences GmbH								
Israel	Derivant Sciences GmbH	DERMAVANT	5, 42, 44	310975	Nov-18-2018	310975	Jun-1-2020	Registered	Nov-18-2028
Israel	Derivant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Israel	Derivant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Israel	Derivant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
Japan	Derivant Sciences GmbH	DERMAVANT	5, 44	2016-087719	Aug-12-2016	5927339	Mar-3-2017	Registered	Mar-3-2027
Japan	Derivant Sciences GmbH	DERMAVANT	42	2018-142531	Nov-16-2018	6209506	Dec-20-2019	Registered	Dec-20-2029
Japan	Derivant Sciences GmbH	QNUVU	5	2020-131502	Oct-23-2020			Pending	
Japan	Derivant Sciences GmbH	TAQTEF	5	2020-101828	Aug-18-2020	6355472	Feb-24-2021	Registered	Feb-24-2031
Japan	Derivant Sciences GmbH	VTAMA	5	2020-101827	Aug-18-2020	6355471	Feb-24-2021	Registered	Feb-24-2031
Japan	Derivant Sciences GmbH	ブイタマ (bu-i-ta-ma)	5	2020-125155	Oct-9-2020	6382722	Apr-26-2021	Registered	Apr-26, 2031
Japan	Derivant Sciences GmbH	ビトマ (bi-to-a-ma)	5	2020-125157	Oct-9-2020	6382723	Apr-26-2021	Registered	Apr-26-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Der mavant Sciences GmbH								
Japan	Der mavant Sciences GmbH	ヴイタマ (Vi-ta-ma)	5	2020-125158	Oct-9-2020			Pending	
Japan	Der mavant Sciences GmbH	ヴィタマー (Vi-ta-ma)	5	2020-125156	Oct-9-2020	6373887	Apr-6-2021	Registered	Apr-6-2031
Japan	Der mavant Sciences GmbH	タクテイフ (ta-ku-thi-fu)	5	2020-125159	Oct-9-2020	6382060	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	タクテフ (ta-ku-te-fu)	5	2020-125160	Oct-9-2020	6382061	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	タークテフ (ta-ku-te-fu)	5	2020-125161	Oct-9-2020	6382062	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	キユヌーゾ (kyu-nuu-bu)	5	2020-131506	Oct-23-2020	6382083	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	クヌーゾ (ku-nuu-bu)	5	2020-131504	Oct-23-2020	6382081	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	クヌーゾ (ku-nuu-bu)	5	2020-131503	Oct-23-2020	6382080	Apr-23-2021	Registered	Apr-23-2031
Japan	Der mavant Sciences GmbH	クヌゾ (ku-nu-bu)	5	2020-131505	Oct-23-2020	6382082	Apr-23-2021	Registered	Apr-23-2031
Korea (South)	Der mavant Sciences GmbH	DERMAVANT	5, 42, 44	40-2018-0160518	Nov-19-2018	40-1501617	Jul-19-2019	Registered	Jul-19-2029
Korea (South)	Der mavant Sciences	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
Korea (South)	Dermaavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Korea (South)	Dermaavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
Mexico	Dermaavant Sciences GmbH	DERMAVANT	5	2132686	Nov-21-2018			Pending	
Mexico	Dermaavant Sciences GmbH	DERMAVANT	42	2132687	Nov-21-2018	1971103	Feb-18-2019	Registered	Nov-21-2028
Mexico	Dermaavant Sciences GmbH	Dermaavant Drop Logo	5, 42, 44	1484337	Jun-11-2019	1484337	Jun-11-2019	Registered	Jun-11-2029
Mexico	Dermaavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Mexico	Dermaavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Mexico	Dermaavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
New Zealand	Dermaavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
New Zealand	Dermaavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
New Zealand	Dermaavant Sciences	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Der mavant Sciences GmbH								
Norway	Der mavant Sciences GmbH	DERMAVANT	5, 42, 44	201815392	Nov-16-2018	308011	Jan-28-2020	Registered	Nov-16-2028
Norway	Der mavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Norway	Der mavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Norway	Der mavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
Russian Federation	Der mavant Sciences GmbH	DERMAVANT	5, 42, 44	2018750535	Nov-19-2018	773759	Sep-1-2020	Registered	Nov-19-2028
Russian Federation	Der mavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Russian Federation	Der mavant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
Russian Federation	Der mavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
Singapore	Der mavant Sciences GmbH	DERMAVANT	5, 42, 44	40201824037W	Nov-19-2018	40201824037W	Nov-19-2018	Registered	Nov-19-2028
Singapore	Der mavant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
Singapore	Der mavant Sciences	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031



COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
	Dermaavant Sciences GmbH								
Singapore	Dermaavant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	DERMAVANT	5	06389/2020	May-11-2020	746832	May-12-2020	Registered	May-11-2030
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	DERMAVANT	5, 41, 44	59579/2016	Aug-12-2016	697826	Jan-17-2017	Registered	Aug-12-2026
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	DERMAVANT	42	81682/2018	Nov-16-2018	729618	Apr-10-2019	Registered	Nov-16-2028
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	Drop Logo	5, 42, 44	82858/2018	Dec-11-2018	733961	Jul-22-2019	Registered	Dec-11-2028
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	QNUVU	5	10441/2020	Jul-24-2020	750067	Jul-24-2020	Registered	Jul-24-2030
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	TAQTEF	5	10440/2020	Jul-24-2020	756914	Dec-21-2020	Registered	Jul-24-2030
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	VTAMA	5	10439/2020	Jul-24-2020	750186	Jul-29-2020	Registered	Jul-24-2030
	Dermaavant Sciences GmbH								
Switzerland	Dermaavant Sciences GmbH	V Logo in color	5	07453/2021	May-10-2021			Pending	
	Dermaavant Sciences GmbH								
United Kingdom	Dermaavant Sciences GmbH	DERMAVANT	42	00003354022	Nov-16-2018	00003354022	Feb-8-2019	Registered	Nov-16-2028
	Dermaavant Sciences GmbH								
United Kingdom	Dermaavant Sciences GmbH	DERMAVANT	5, 44	3179905	Aug-11-2016	3179905	Aug-7-2020	Registered	Aug-11-2026

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
	GmbH								
United Kingdom	Derivant Sciences GmbH	DERMAVANT	5, 44	UK00915751217	Aug-11-2016	UK00915751217	Aug-18-2020	Registered	Aug-11-2026
United Kingdom	Derivant Sciences GmbH	DERMAVANT	42	UK00917986410	Nov-16-2018	UK00917986410	May-11-2019	Registered	Nov-16-2028
United Kingdom	Derivant Sciences GmbH	Derivant Drop Logo	5, 42, 44	UK00801484337	Jun-11-2019	UK00801484337	Jun-11-2019	Registered	Jun-11-2029
United Kingdom	Derivant Sciences GmbH	QNUVU	5	1579340	Jan-18-2021	1579340	Jan-18-2021	Pending	Jan-18-2031
United Kingdom	Derivant Sciences GmbH	TAQTEF	5	1579289	Jan-18-2021	1579289	Jan-18-2021	Pending	Jan-18-2031
United Kingdom	Derivant Sciences GmbH	VTAMA	5	1580275	Jan-18-2021	1580275	Jan-18-2021	Pending	Jan-18-2031
United States of America	Derivant Sciences GmbH	DERMAVANT	5	87/076,312	Jun-18-2016	5440964	Apr-10-2018	Registered	Apr-10-2028
United States of America	Derivant Sciences GmbH	DERMAVANT	44	87/133,693	Aug-10-2016	5441037	Apr-10-2018	Registered	Apr-10-2028
United States of America	Derivant Sciences GmbH	DERMAVANT	5, 44	87/788,429	Feb-7-2018	5796949	Jul-9-2019	Registered	Jul-9-2029
United States of America	Derivant Sciences GmbH	DERMAVANT	42	88/192,019	Nov-13-2018	5935231	Dec-17-2019	Registered	Dec-17-2029
United States of	Derivant Sciences	Derivant Drop Logo	5, 42, 44	88/230,292	Dec-14-2018	5935386	Dec-17-2019	Registered	Dec-17-2029

COUNTRY	OWNER	TM	CLASSES	APPLICATION NO	APPLICATION DATE	REGISTRATION NO	REGISTRATION DATE	TRADEMARK STATUS	RENEWAL DUE
America	GmbH								
United States of America	Dermavant Sciences GmbH		5	90/473,679	Jan-19-2021			Pending	
United States of America	Dermavant Sciences GmbH	TAQTEF	5	90/401,644	Dec-22-2020			Pending	
United States of America	Dermavant Sciences GmbH	VTAWMA	5	90/401,654	Dec-22-2020			Pending	
United States of America	Dermavant Sciences GmbH	V Logo in color	5	90/702,950	May-11-2021			Pending	

TRADEMARK  
REEL: 007298 FRAME: 0079

RECORDED: 05/18/2021